The U.S. hemophilia treatment market offers therapeutic options for treating bleeding disorders like hemophilia A and B. Recombinant factor VIII and IX concentrates are commonly used to prevent and control bleeding in patients. Advances in injectable and extended half-life therapies have improved quality of life for many.

U.S. hemophilia treatment market size is expected to reach US$ 6.81 Bn by 2031, from US$ 4.21 Bn in 2023, exhibiting a compound annual growth rate (CAGR) of 6.2% during the forecast period.

Key Takeaways

Key players operating in the U.S. hemophilia treatment are Takeda Pharmaceutical Company Limited, Sanofi Octapharma  AG, Swedish Orphan Biovitrum AB, Baxter International Inc.,Biogen Inc. Takeda dominates the market for hemophilia A treatment in the U.S. with Advate and Adynovate. Growing awareness about prophylactic management and availability of novel therapies are fueling demand in the market. Companies are investing in development of gene therapy, which offers potential one-time treatment for hemophilia.

U.S. Hemophilia Treatment Market Healthcare expenditure and increasing demand for preventive care in the U.S. is driving growth of the hemophilia treatment market. Prophylactic treatment helps prevent bleeding episodes and associated health issues. Growing patient assistance programs further improve access and adherence to treatment. Novel extended half-life factor therapies offer less frequent infusions reducing burden on patients and caregivers.

Technological advancement in development and production of recombinant coagulation factors has transformed hemophilia treatment landscape. Development of longer acting factors and subcutaneous formulations offers convenience and improves compliance. Gene therapy holds promise for potential one-time treatment. Ongoing trials are evaluating safety and efficacy.

Get More Insight On : U.S. Hemophilia Treatment Market

Get this Report in Japanese Language: 米国の血友病治療市場

Get this Report in Korean Language: 미국혈우병치료시장